Myriad Genetics Delivers 56% Sequential Increase in Quarterly Revenue; Test Volumes Reach 90% of Pre-COVID-19 Level at End of Quarter
Go back to Myriad Genetics Delivers 56% Sequential Increase in Quarterly Revenue; Test Volumes Reach 90% of Pre-COVID-19 Level at End of Quarter| Myriad Genetics, Inc. (NASDAQ: MYGN) | Delayed: 4.63 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.63 | 52 Week High | $45.34 | |||
| Open | $4.63 | 52 Week Low | $15.92 | |||
| Day High | $4.63 | P/E | 1.99 | |||
| Day Low | $4.63 | EPS | $2.33 | |||
| Volume | 228 | |||||
